oral glutathione bioavailability human trial A Targeted Metabolomic Assessment of and Safety in Humans: A Randomized Crossover Clinical Bioavailability Study of an Innovative

The 'one-size-fits-all' approach is rapidly becoming a relic of the past

Constantinescu CS, Hilliard B, Ventura E, Rostami A (1997) Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis

1 Introduction 1.1 Atherosclerosis and coronary artery disease Coronary artery disease (CAD) is a cardiovascular condition occuring due to atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive ( Inflammation plays a key role in the formation of atherosclerotic plaquesthe primary pathological mechanism underlying CAD ( (IFN- ) and tumour necrosis factor (TNF)- , produced by immune cells, endothelial cells, platelets and fibroblasts are associated with atherosclerosis onset and progression

FDA draft guidance on New Approach Methodologies (NAMs): A structural shift in drug development strategy